Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr-Jun;20(2):2635.
doi: 10.18549/PharmPract.2022.2.2635. Epub 2022 Mar 31.

Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study

Sirinoot Palapinyo  1 , Jettanong Klaewsongkram  2 , Virote Sriuranpong  3 , Nutthada Areepium  4
Affiliations

Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study

Sirinoot Palapinyo et al. Pharm Pract (Granada). 2022 Apr-Jun.

Abstract

Background: Oxaliplatin is a third-generation platinum compound that has efficacy against colorectal cancer. Hypersensitivity reactions during oxaliplatin infusion are a key problem during its use, with the varying incidences and deficiencies of clearly identified risk factors.

Objective: To determine the incidence, severity and risk factors of oxaliplatin-related hypersensitivity reaction (HSR).

Method: This retrospective study investigated 245 colorectal cancer patients (1,690 treatment cycles) receiving care at King Chulalongkorn Memorial Hospital, Thai Red Cross society between January 1, 2015 and December 31, 2019. The patients' demographic data, laboratory data and clinical features suggesting hypersensitivity reactions to oxaliplatin were reviewed. The Fisher's Exact test and unpaired t-test were used to determine the differences among patients with and without oxaliplatin HSR. The potential risk factors for oxaliplatin HSR were analyzed for statistical significance by logistic regression.

Results: A total of 245 colorectal cancer patients (1,690 treatment cycles) were included in this study. The incidence of oxaliplatin HSR was 37.96%, according to the US National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (NTCAE) version 5.0, grade 1, grade 2 and higher grades were 27.35% (67 patients), 6.53% (16 patients) and 4.08% (10 patients), respectively. The proportion of male patients and patients with a history of prior exposure to platinum-based chemotherapy were statistically higher in the HSR group. The eosinophil count and serum creatinine level were also significantly greater in the HSR group. On the contrary, the total lymphocyte count and serum albumin level were significantly lower in the HSR group. The multivariate logistic regression found 5 risk factors with a significant difference. Male gender, prior exposure to platinum-based chemotherapy and elevated eosinophil count were associated with increased risk of oxaliplatin HSR, whereas elevated monocyte count and elevated serum albumin were protective factors for the development of oxaliplatin HSR.

Conclusion: Colorectal cancer patients treated with an oxaliplatin-based regimen with male gender, prior exposure to platinum-based chemotherapy and elevated eosinophil count have a greater risk of oxaliplatin related hypersensitivity reactions.

Keywords: Colorectal cancer; Hypersensitivity reactions; Oxaliplatin; Risk factors.

PubMed Disclaimer

References

    1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer:incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103. doi: 10.5114/pg.2018.81072. - DOI - PMC - PubMed
    1. Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329–59. doi: 10.6004/jnccn.2021.0012. - DOI - PubMed
    1. Lohsiriwat V, Chaisomboon N, Pattana-Arun J. Current Colorectal Cancer in Thailand. Ann Coloproctol. 2020;36(2):78–82. doi: 10.3393/ac.2020.01.07. - DOI - PMC - PubMed
    1. Huang W-K, Hsu H-C, Chang S-H, et al. Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer:A Controlled Interrupted Time Series Analysis. Front Pharmacol. 2021;12:693009. doi: 10.3389/fphar.2021.693009. - DOI - PMC - PubMed
    1. Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer:a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44–70. doi: 10.1093/annonc/mdx738. - DOI - PubMed

LinkOut - more resources